74,448 XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| R. Erik Holmlin | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.47 per share. | 14 Mar 2025 | 198 | 1,783 (0%) | 0% | 3.5 | 687 | Common Stock |
| R. Erik Holmlin | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 17,449 | 17,449 | - | - | Stock Option (Right to Buy) | |
| Mark Borodkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 6,966 | 6,966 | - | - | Stock Option (Right to Buy) | |
| Mark Adamchak | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 3,029 | 3,029 | - | - | Stock Option (Right to Buy) | |
| Alka Chaubey | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 6,966 | 6,966 | - | - | Stock Option (Right to Buy) | |
| Jonathan V. Dixon | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 6,559 | 6,559 | - | - | Stock Option (Right to Buy) | |
| R. Erik Holmlin | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.73 per share. | 15 Feb 2025 | 51 | 1,981 (0%) | 0% | 5.7 | 292 | Common Stock |
| Mark Borodkin | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.75 per share. | 15 Feb 2025 | 20 | 1,001 (0%) | 0% | 5.8 | 115 | Common Stock |
| Mark Adamchak | Principal Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.75 per share. | 15 Feb 2025 | 4 | 270 (0%) | 0% | 5.8 | 23 | Common Stock |
| Alka Chaubey | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.72 per share. | 15 Feb 2025 | 18 | 737 (0%) | 0% | 5.7 | 103 | Common Stock |
| Jonathan V. Dixon | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.67 per share. | 15 Feb 2025 | 6 | 294 (0%) | 0% | 5.7 | 34 | Common Stock |
| Mark Adamchak | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Mark Borodkin | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.48 per share. | 11 Sep 2024 | 3,568 | 61,283 (0%) | 0% | 0.5 | 1,713 | Common Stock |
| Alka Chaubey | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.48 per share. | 11 Sep 2024 | 3,075 | 45,323 (0%) | 0% | 0.5 | 1,476 | Common Stock |
| Christopher J. Twomey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| David L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Kristiina Vuori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Albert A. Luderer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Hannah Mamuszka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Yvonne Linney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Vincent Jung-Fai Wong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Aleksandar Rajkovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| R. Erik Holmlin | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 204,000 | 204,000 | - | - | Stock Option (Right to Buy) | |
| R. Erik Holmlin | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 44,000 | 121,813 (0%) | 0% | 0 | Common Stock | |
| Mark Borodkin | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Mark Borodkin | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 16,000 | 64,698 (0%) | 0% | 0 | Common Stock | |
| Alka Chaubey | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 16,000 | 48,245 (0%) | 0% | 0 | Common Stock | |
| Alka Chaubey | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Jonathan V. Dixon | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 68,000 | 68,000 | - | - | Stock Option (Right to Buy) | |
| Jonathan V. Dixon | GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 14,500 | 18,025 (0%) | 0% | 0 | Common Stock | |
| Gulsen Kama | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Gulsen Kama | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 16,000 | 16,000 (0%) | 0% | 0 | Common Stock | |
| R. Erik Holmlin | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.27 per share. | 15 Feb 2024 | 3,073 | 77,663 (0%) | 0% | 1.3 | 3,903 | Common Stock |
| Mark Borodkin | CHIEF OPERATING OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.27 per share. | 15 Feb 2024 | 1,229 | 48,644 (0%) | 0% | 1.3 | 1,561 | Common Stock |
| Alka Chaubey | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.27 per share. | 15 Feb 2024 | 1,081 | 31,487 (0%) | 0% | 1.3 | 1,373 | Common Stock |
| Jonathan V. Dixon | GENERAL COUNSEL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.27 per share. | 15 Feb 2024 | 402 | 3,525 (0%) | 0% | 1.3 | 511 | Common Stock |
| Christopher J. Twomey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| David L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Kristiina Vuori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Albert A. Luderer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Hannah Mamuszka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Yvonne Linney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Vincent Jung-Fai Wong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Aleksandar Rajkovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| R. Erik Holmlin | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.64 per share. | 16 May 2023 | 15,000 | 806,474 (2%) | 0% | 0.6 | 9,639 | Common Stock |
| R. Erik Holmlin | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.66 per share. | 12 May 2023 | 50,141 | 791,474 (2%) | 0% | 0.7 | 33,093 | Common Stock |
| Mark Borodkin | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.66 per share. | 12 May 2023 | 41,496 | 297,842 (0%) | 0% | 0.7 | 27,387 | Common Stock |
| Christopher Stewart | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.67 per share. | 12 May 2023 | 50,000 | 281,373 (0%) | 0% | 0.7 | 33,415 | Common Stock |
| R. Erik Holmlin | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 300,000 | 841,615 (2%) | 0% | 0 | Common Stock | |
| R. Erik Holmlin | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 1,400,000 | 1,400,000 | - | - | Stock Option (Right to Buy) | |
| Mark Borodkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 560,000 | 560,000 | - | - | Stock Option (Right to Buy) | |
| Mark Borodkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 120,000 | 339,338 (0%) | 0% | 0 | Common Stock | |
| Christopher Stewart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 490,000 | 490,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Stewart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 105,000 | 231,373 (0%) | 0% | 0 | Common Stock | |
| Alka Chaubey | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 120,000 | 124,794 (0%) | 0% | 0 | Common Stock | |
| Alka Chaubey | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 560,000 | 560,000 | - | - | Stock Option (Right to Buy) | |
| Yvonne Linney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2022 | 20,000 | 60,923 | - | - | Stock Option (Right to Buy) | |
| Yvonne Linney | Director | Sale of securities on an exchange or to another person at price $ 3.62 per share. | 15 Aug 2022 | 20,000 | 0 (0%) | 0% | 3.6 | 72,402 | Common Stock |
| Yvonne Linney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.38 per share. | 15 Aug 2022 | 20,000 | 20,000 (0%) | 0% | 0.4 | 7,600 | Common Stock |
| David L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 44,470 | 0 | - | - | Stock Option (Right to Buy) | |
| David L. Barker | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.51 per share. | 07 Jul 2022 | 44,470 | 58,364 (0%) | 0% | 0.5 | 22,680 | Common Stock |
| Christopher J. Twomey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 164,422 | 164,422 | - | - | Stock Option (right to buy) | |
| David L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 164,422 | 164,422 | - | - | Stock Option (right to buy) | |
| Kristiina Vuori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 164,422 | 164,422 | - | - | Stock Option (right to buy) | |
| Albert A. Luderer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 164,422 | 164,422 | - | - | Stock Option (right to buy) | |
| Hannah Mamuszka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 164,422 | 164,422 | - | - | Stock Option (right to buy) | |
| Yvonne Linney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 164,422 | 164,422 | - | - | Stock Option (right to buy) | |
| Vincent Jung-Fai Wong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 164,422 | 164,422 | - | - | Stock Option (right to buy) | |
| Aleksandar Rajkovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 164,422 | 164,422 | - | - | Stock Option (right to buy) | |
| David L. Barker | Director | Purchase of securities on an exchange or from another person at price $ 1.60 per share. | 16 May 2022 | 10,000 | 13,894 (0%) | 0% | 1.6 | 16,000 | Common Stock |
| Christopher Stewart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.56 per share. | 13 May 2022 | 60,000 | 121,579 (0%) | 0% | 0.6 | 33,600 | Common Stock |
| Christopher Stewart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2022 | 60,000 | 117,500 | - | - | Stock Option (Right to Buy) | |
| R. Erik Holmlin | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.41 per share. | 12 May 2022 | 50,141 | 538,556 (1%) | 0% | 1.4 | 70,699 | Common Stock |
| Mark Borodkin | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.41 per share. | 12 May 2022 | 41,496 | 216,669 (0%) | 0% | 1.4 | 58,509 | Common Stock |
| Aleksandar Rajkovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 194,986 | 194,986 | - | - | Stock Option (right to buy) | |
| R. Erik Holmlin | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 1,400,000 | 1,400,000 | - | - | Stock Option (Right to Buy) | |
| Mark Borodkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 650,000 | 650,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Stewart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 550,000 | 550,000 | - | - | Stock Option (Right to Buy) | |
| Alka Chaubey | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 550,000 | 550,000 | - | - | Stock Option (Right to Buy) | |
| Richard Shippy | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 550,000 | 550,000 | - | - | Stock Option (Right to Buy) | |
| Soheil Shams | Chief Informatics Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 550,000 | 550,000 | - | - | Stock Option (Right to Buy) | |
| Vincent Jung-Fai Wong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2021 | 122,054 | 122,054 | - | - | Stock Option (Right to Buy) | |
| R. Erik Holmlin | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.98 per share. | 29 Nov 2021 | 2,200 | 2,200 (0%) | 0% | 4.0 | 8,767 | Common Stock |
| R. Erik Holmlin | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.98 per share. | 29 Nov 2021 | 150 | 5,025 (0%) | 0% | 4.0 | 597 | Common Stock |
| R. Erik Holmlin | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.99 per share. | 29 Nov 2021 | 2,675 | 4,875 (0%) | 0% | 4.0 | 10,673 | Common Stock |
| Christopher Stewart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.56 per share. | 19 Nov 2021 | 22,500 | 55,500 (0%) | 0% | 0.6 | 12,600 | Common Stock |
| Christopher Stewart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2021 | 22,500 | 177,500 | - | - | Stock Option (Right to Buy) | |
| Soheil Shams | Chief Informatics Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Soheil Shams | Chief Informatics Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2021 | 5,325,378 | 5,325,378 (15%) | 15% | - | Common Stock | |
| Christopher J. Twomey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 40,751 | 40,751 | - | - | Stock Option (right to buy) | |
| David L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 40,751 | 40,751 | - | - | Stock Option (right to buy) | |
| Kristiina Vuori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 40,751 | 40,751 | - | - | Stock Option (right to buy) | |
| Albert A. Luderer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 40,751 | 40,751 | - | - | Stock Option (right to buy) | |
| Hannah Mamuszka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 40,751 | 40,751 | - | - | Stock Option (right to buy) | |
| Yvonne Linney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 40,751 | 40,751 | - | - | Stock Option (right to buy) | |
| Richard Shippy | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Christopher J. Twomey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 7,528 | 7,528 | - | - | Stock Option (right to buy) | |
| David L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 7,528 | 7,528 | - | - | Stock Option (right to buy) | |
| Kristiina Vuori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 7,528 | 7,528 | - | - | Stock Option (right to buy) | |
| Albert A. Luderer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 7,528 | 7,528 | - | - | Stock Option (right to buy) | |
| Hannah Mamuszka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 7,528 | 7,528 | - | - | Stock Option (right to buy) | |
| Yvonne Linney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 7,528 | 7,528 | - | - | Stock Option (right to buy) | |
| Robert J. Priar | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Stewart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 May 2021 | 25,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Stewart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.56 per share. | 26 May 2021 | 25,000 | 33,000 (0%) | 0% | 0.6 | 14,000 | Common Stock |
| R. Erik Holmlin | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 290,000 | 585,191 (1%) | 0% | 0 | Common Stock | |
| R. Erik Holmlin | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 290,000 | 295,191 (0%) | 0% | 0 | Common Stock | |
| Mark Borodkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 240,000 | 252,086 (0%) | 0% | 0 | Common Stock | |
| R. Erik Holmlin | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 775,000 | 775,000 | - | - | Stock Option (Right to Buy) | |
| Mark Borodkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Stewart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Alka Chaubey | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Stewart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 6.00 per share. | 22 Jan 2021 | 8,000 | 8,000 (0%) | 0% | 6 | 48,000 | Common Stock |
| Christopher Stewart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 350,000 | 350,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Stewart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Alka Chaubey | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2020 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Christopher J. Twomey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 44,470 | 44,470 | - | - | Stock Option (Right to Buy) | |
| David L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 44,470 | 44,470 | - | - | Stock Option (right to buy) | |
| Kristiina Vuori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 44,470 | 44,470 | - | - | Stock Option (Right to Buy) | |
| Albert A. Luderer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 44,470 | 44,470 | - | - | Stock Option (Right to Buy) | |
| Hannah Mamuszka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 44,470 | 44,470 | - | - | Stock Option (Right to Buy) | |
| Yvonne Linney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 44,470 | 44,470 | - | - | Stock Option (Right to Buy) | |
| Hannah Mamuszka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2020 | 80,923 | 80,923 | - | - | Stock Option (right to buy) | |
| Yvonne Linney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2020 | 80,923 | 80,923 | - | - | Stock Option (right to buy) | |
| Christopher J. Twomey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Apr 2020 | 45,000 | 45,000 | - | - | Common Stock Warrants (right to buy) | |
| Christopher J. Twomey | Director | Grant, award, or other acquisition of securities at price $ 0.32 per share. | 06 Apr 2020 | 45,000 | 64,500 (0%) | 0% | 0.3 | 14,400 | Common Stock |
| R. Erik Holmlin | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2020 | 290,000 | 290,000 | - | - | Stock Option (Right to Buy) | |
| Warren Robinson | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2020 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Mark Borodkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2020 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Heather Adams | Chief Administrative Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2020 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Christopher J. Twomey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Oct 2019 | 9,500 | 9,500 | - | - | Common Stock Warrants (right to buy) | |
| Christopher J. Twomey | Director | Grant, award, or other acquisition of securities at price $ 0.85 per share. | 23 Oct 2019 | 9,500 | 19,500 (0%) | 0% | 0.9 | 8,075 | Common Stock |
| Christopher J. Twomey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 21,911 | 21,911 | - | - | Stock Option (right to buy) | |
| David L. Barker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 21,911 | 21,911 | - | - | Stock Option (right to buy) | |
| Kristiina Vuori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 30,274 | 30,274 | - | - | Stock Option (right to buy) | |
| Darren Cai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 21,911 | 21,911 | - | - | Stock Option (right to buy) | |
| Albert A. Luderer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 21,911 | 21,911 | - | - | Stock Option (right to buy) | |
| Junfeng Wang | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 21,911 | 21,911 | - | - | Stock Option (right to buy) | |
| Quan Zhou | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2019 | 21,911 | 21,911 | - | - | Stock Option (right to buy) | |
| Michael J. Ward | Former Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| R. Erik Holmlin | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 145,000 | 145,000 | - | - | Stock Option (Right to Buy) | |
| Warren Robinson | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Mark Borodkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2019 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Mark Borodkin | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2019 | 6,000 | 28,219 | - | - | Stock Option (Right to Buy) | |
| Mark Borodkin | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.30 per share. | 18 Jan 2019 | 6,000 | 6,815 (0%) | 0% | 1.3 | 7,800 | Common Stock |
| Christopher J. Twomey | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 10,516 | 10,516 | - | - | Stock Option (Right to Buy) | |
| Michael J. Ward | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 59,590 | 59,590 | - | - | Stock Option (Right to Buy) | |
| R. Erik Holmlin | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 256,540 | 256,540 | - | - | Stock Option (Right to Buy) | |
| Han Cao | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 23,230 | 23,230 | - | - | Stock Option (Right to Buy) | |
| Warren Robinson | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 64,640 | 64,640 | - | - | Stock Option (Right to Buy) | |
| Mark Borodkin | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 59,590 | 59,590 | - | - | Stock Option (Right to Buy) | |
| Darren Cai | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 10,516 | 10,516 | - | - | Stock Option (Right to Buy) | |
| Albert A. Luderer | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 10,516 | 10,516 | - | - | Stock Option (Right to Buy) | |
| Junfeng Wang | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 10,516 | 10,516 | - | - | Stock Option (Right to Buy) | |
| Quan Zhou | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2018 | 10,516 | 10,516 | - | - | Stock Option (Right to Buy) | |
| David L. Barker | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 21 Aug 2018 | 3,894 | 3,894 | - | - | Common Stock Warrants (right to buy) | |
| David L. Barker | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2018 | 10,516 | 10,516 | - | - | Stock Option (Right to Buy) | |
| David L. Barker | None | Purchase of securities on an exchange or from another person at price $ 6.47 per share. | 21 Aug 2018 | 3,894 | 3,894 (0%) | 0% | 6.5 | 25,194 | Common Stock |